In an engaging conversation, Kristin Yarema, President and CEO of Poseida Therapeutics, shares her inspiring journey from pharma to biotech entrepreneurship. She discusses groundbreaking advancements in allogeneic cell therapies and their potential to transform cancer treatment. Kristin reflects on the challenges of her CEO role, the significance of company culture, and effective teamwork. She emphasizes the impact of mentorship and personal growth in careers, underscoring the human stories behind medical innovations.

Kristin Yarema, Ph.D., the newly-appointed CEO of Poseida Therapeutics, dives into the transformative world of CAR T therapeutics. She envisions a future where allogeneic therapies make life-saving treatments widely accessible. Kristin shares her journey from academia to biotech, emphasizing the benefits of strategic collaborations with companies like Astellas and Roche. The conversation highlights the innovative convertible CAR T approach and the ongoing challenges in scalable production for autoimmune diseases, underscoring the critical role of partnerships in advancing cancer treatment.

Poseida Therapeutics' CEO Kristin Yarema discusses the challenges of developing off-the-shelf therapies in CGT sector. She highlights the potential progress in allogeneic therapies by 2024. Topics include nanoparticle delivery, allogeneic T cell therapies, strategic investments, manufacturing scale up, and personal plans for 2024.